Executive Summary

The May 2023 merger of equals between Royal DSM and Firmenich International SA created dsm-firmenich AG, a new powerhouse in the global ingredients sector with a unique and comprehensive portfolio spanning nutrition, health, and beauty. This report provides an exhaustive investment analysis of the merged entity, examining the strategic logic behind its formation, the progress of its complex integration, its positioning within a dynamic competitive landscape, and its financial trajectory through a period of significant transformation. The core strategic objective of the merger is to establish an end-to-end innovation partner for the world’s leading consumer goods companies, a goal that no single competitor can currently match at the same scale.

A pivotal element of the company’s strategy is the announced separation of its Animal Nutrition & Health (ANH) business. This move is designed to de-risk the group from the historical volatility of vitamin pricing and reduce its capital intensity, thereby sharpening its focus on the higher-margin, more resilient, and consumer-proximate segments of Perfumery & Beauty (P&B), Taste, Texture & Health (TTH), and Health, Nutrition & Care (HNC). This portfolio reshaping is already well underway with the divestiture of several non-core assets, including the lucrative sale of its Feed Enzymes Alliance stake.

Financially, dsm-firmenich has demonstrated remarkable resilience and a strong recovery. After a challenging 2023, which was heavily impacted by industry-wide customer destocking and an unprecedented downturn in vitamin prices, the company delivered a significant rebound in 2024 and the first half of 2025. This recovery was driven by the normalization of market conditions, disciplined cost management, and the successful execution of two key self-help initiatives: the merger synergy program and a separate, highly effective vitamin transformation program. The company is firmly on track to deliver its targeted €350 million in annual run-rate EBITDA from merger synergies, with both cost savings and revenue-enhancing cross-selling opportunities contributing meaningfully to profitability.

From a valuation perspective, dsm-firmenich presents a complex case. While the company is executing its strategic plan with discipline—de-leveraging its balance sheet, returning significant capital to shareholders via a €1 billion buyback, and investing in high-growth innovation platforms—its trading multiples have historically reflected the conglomerate structure and the volatility of the ANH segment. The central question for investors is the timeline and extent of a potential valuation re-rating. As the integration matures, the ANH separation is completed, and the financial profile of the “new” dsm-firmenich becomes clearer and more stable, a narrowing of the valuation gap to pure-play peers such as Givaudan appears plausible. The successful execution of the company’s well-defined strategic roadmap over the coming quarters will be the critical determinant of this value crystallization.

---

I. Corporate Profile: A New Leader in Creation & Innovation

This section establishes the foundational identity of the new entity, detailing the strategic logic behind its formation and its operational structure.

A. The Merger of Equals: Strategic Rationale and Integration Roadmap

The creation of dsm-firmenich AG represents one of the most significant strategic consolidations in the global ingredients sector in recent years. The transaction, structured as a merger of equals, officially closed on May 8, 2023, following its announcement on May 31, 2022, and the receipt of all necessary regulatory and competition clearances by early April 2023.¹ The new entity is a Swiss-domiciled company with a primary listing on the Euronext Amsterdam exchange, reflecting the dual heritage of its Dutch (DSM) and Swiss (Firmenich) predecessors.²

The ownership structure at inception was designed to reflect the “merger of equals” principle, with legacy Royal DSM N.V. shareholders owning 65.5% of the combined company. Shareholders of the privately-held Firmenich International SA received a 34.5% stake in dsm-firmenich AG, in addition to €3.5 billion in cash, subject to adjustments.⁴

The fundamental strategic rationale for the merger was to create a uniquely comprehensive, end-to-end innovation partner for the global nutrition, health, and beauty industries.² The combination brings together two highly complementary businesses:

• Legacy DSM: A global leader in health, nutrition, and bioscience, with world-class capabilities in vitamins, nutritional lipids, human milk oligosaccharides (HMOs), and other science-backed health ingredients.⁴
• Legacy Firmenich: The world’s largest privately-owned fragrance and taste company, renowned for its creativity, world-class research in scent and flavor, and leadership in sustainable and renewable ingredients.⁴

By integrating these capabilities, dsm-firmenich aims to offer its customers a “one-stop-shop” for product development that is difficult for competitors to replicate. This integrated approach allows the company to partner with clients on multifaceted solutions that address taste, texture, health, and scent simultaneously, fostering deeper, more strategic relationships. The first integrated annual report for the fiscal year 2023 was published in early 2024, marking a key milestone in establishing a unified reporting and governance framework for the new entity.⁷

The strategic value of this merger extends beyond mere operational scale; it effectively creates a new market category of an “integrated sensory and nutritional solutions provider.” While competitors like Givaudan and IFF are formidable in flavors and fragrances, and players like ADM and Cargill are strong in nutritional ingredients, no single entity possesses the same depth and breadth across both domains at the scale of dsm-firmenich. This unique positioning allows the company to approach a customer, such as a dairy product manufacturer, with a holistic value proposition. As demonstrated in a case study with its Mexican dairy customer Alpura, the company can provide not only the flavor profile but also the texture components, the health-enhancing ingredients like vitamins and probiotics, and even insights into sustainable packaging.⁷ This capability transforms the company from a simple ingredient supplier into an integral R&D partner, creating stickier customer relationships and supporting the company’s ambitious revenue synergy targets.

B. Post-Merger Business Architecture: Four Pillars of Operation

Following the merger, dsm-firmenich was organized into four distinct business units, each designed to leverage the combined strengths of the legacy companies and target specific end markets.⁶

1. Perfumery & Beauty (P&B): This unit is a global leader in its field, combining Firmenich’s historic strength in fine fragrance, consumer fragrance (for products like soaps and detergents), and fragrance ingredients with DSM’s well-established personal care and aroma portfolio. It serves the full spectrum of the market, from luxury perfumes to mass-market beauty and personal care items.⁹
2. Taste, Texture & Health (TTH): This business integrates Firmenich’s taste division with DSM’s extensive range of food and beverage ingredients. Its comprehensive portfolio includes flavors, enzymes, cultures, hydrocolloids, and nutritional ingredients for applications in dairy, beverages, savory foods, bakery, confectionery, and the rapidly growing plant-based food sector.⁸
3. Health, Nutrition & Care (HNC): This unit is focused on science-backed solutions for human health. It provides essential nutrients and active ingredients for dietary supplements, early-life nutrition (infant formula), medical nutrition, and pharmaceutical applications. Key product categories include vitamins, nutritional lipids (such as omega-3s), HMOs, carotenoids, and active pharmaceutical ingredients.⁹
4. Animal Nutrition & Health (ANH): This is the legacy DSM business dedicated to animal health and farming. It is a leading global supplier of feed additives, including vitamins, enzymes, eubiotics, and mycotoxin risk management solutions for livestock, poultry, aquaculture, and pets.⁸ As part of a major strategic pivot announced in 2024, this segment is in the process of being separated from the group.

Based on the financial results for the first half of 2025, the revenue contribution from these segments was: Perfumery & Beauty at €1,989 million, Taste, Texture & Health at €1,686 million, Health, Nutrition & Care at €1,072 million, and Animal Nutrition & Health at €1,751 million.¹¹ The substantial revenue base of the ANH segment underscores the significance of its planned separation as the company reorients its portfolio toward consumer-focused end markets.

C. Geographic Footprint and Revenue Diversification

dsm-firmenich boasts a truly global operational footprint, a critical asset for serving multinational consumer goods clients and sourcing raw materials worldwide. The company operates approximately 340 sites across nearly 60 countries, supported by a diverse team of almost 30,000 employees.⁷ This extensive network facilitates localized innovation, manufacturing, and customer service while leveraging global economies of scale.

The company’s revenue is well-diversified geographically, mitigating risks associated with dependence on any single market. The sales distribution for the full fiscal year 2024 provides a clear picture of this balance.

Region	Net Sales (FY 2024, € millions)	% of Total Sales
Rest of EMEA	3,938	30%
North America	2,928	23%
Rest of Asia	2,316	18%
Latin America	1,887	15%
China	1,096	9%
Netherlands	420	3%
Switzerland	214	2%
Total	12,799	100%
Source: dsm-firmenich 2024 Annual Report 12

This geographic mix reveals a strategic balance. The mature, high-margin markets of North America and EMEA constitute a stable foundation, accounting for a combined 56% of sales. Simultaneously, the company has significant exposure to high-growth emerging economies in Asia and Latin America, which together represent 42% of revenue. This positioning allows dsm-firmenich to capture the rapid expansion of the middle class and increasing consumer demand in these regions, which are forecast to be the primary drivers of growth for the personal care, food, and nutrition industries.¹³

However, this global footprint is not without risk. The 9% direct revenue exposure to China, combined with the country’s critical role in global supply chains for certain raw materials and intermediates, makes the company susceptible to geopolitical tensions, trade policy shifts, and evolving local regulations.¹⁶ The company’s operational decisions, such as the closure of vitamin production facilities in China as part of its restructuring program, highlight the complex strategic calculus required to manage this exposure effectively.¹⁹ While the growth opportunity in Asia is a key pillar of the investment thesis, the ability to navigate the region’s dynamic and often challenging operating environment remains a critical factor for long-term success.

D. Leadership and Organizational Structure

To steer the complex integration and execute its ambitious strategy, dsm-firmenich has established a balanced leadership team comprising senior executives from both legacy organizations. The Executive Committee is led by Co-CEOs Geraldine Matchett and Dimitri de Vreeze, a structure designed to ensure continuity and a unified vision during the initial post-merger phase.² This dual-leadership model, combined with an executive team representing the full breadth of the new company’s diversity and skillsets, is crucial for fostering a cohesive corporate culture and driving operational alignment. The company maintains dual headquarters in Kaiseraugst, Switzerland, and Maastricht, Netherlands, honoring the deep roots and heritage of both Firmenich and DSM.³

II. Industry Dynamics & Competitive Landscape

dsm-firmenich operates at the intersection of several large, resilient, and growing industries. Its performance and strategic decisions are shaped by powerful secular trends, an intensely competitive environment, and a complex global regulatory landscape.

A. Market Dynamics Across Core Segments

The company’s three core consumer-focused segments are supported by robust, long-term growth drivers.

• Nutrition & Health Ingredients: This is a vast and expanding market, underpinned by powerful global megatrends. Key drivers include heightened consumer health consciousness, the increasing demand for clean-label, natural, and sustainable ingredients, the rise of personalized nutrition, and the ongoing protein transition towards plant-based and alternative sources.²¹ The global nutritional ingredients market was valued at over $182 billion in 2022 and is projected to grow to approximately $325 billion by 2031, implying a compound annual growth rate (CAGR) of around 7.5%.²⁵ Specific high-growth niches within this market include ingredients for gut health (probiotics, prebiotics, and postbiotics), cognitive health (nootropics and adaptogens), and specialized nutrition tailored to the needs of specific consumer groups, such as individuals using GLP-1 weight-management medications.²¹
• Fragrance & Flavor (F&F) Industry: The F&F market is characterized by its consolidated nature and steady, non-cyclical growth, with various market reports projecting a CAGR in the range of 4% to 5.5%.²⁷ The global market was valued at approximately $30 billion to $36 billion in the 2023-2024 period.²⁷ Growth is fueled by the rising consumption of processed and convenience foods, particularly in emerging markets, and the increasing use of sophisticated fragrances in personal care, home care, and fine fragrance products. A dominant trend across the industry is the strong consumer and regulatory push towards natural, sustainable, and “clean-label” flavor and fragrance solutions, driving significant R&D investment in biotechnology, fermentation, and green chemistry.²⁸
• Beauty & Personal Care Ingredients: This market, valued at approximately $13 billion to $15 billion in 2024, is forecast to grow at a healthy CAGR of 4.4% to 6.0%.³¹ The market is driven by increasing consumer spending on skincare, hair care, and cosmetics, with a strong emphasis on product efficacy and performance. Key growth drivers include the demand for multifunctional ingredients that offer multiple benefits (e.g., moisturizing and UV protection), high-performance anti-aging and skin health products, and the pervasive “clean beauty” movement, which favors natural, organic, and sustainable formulations.¹⁴ While Europe remains the largest regional market, Asia-Pacific is experiencing the fastest growth, fueled by rising disposable incomes and sophisticated consumer demand.¹³

A critical theme that cuts across all these segments is the convergence of “Health & Wellness” with “Sensory Experience.” Consumers are no longer willing to compromise; they demand products that are not only healthy, nutritious, and sustainable but also deliver exceptional taste, texture, and scent. This is precisely the nexus where dsm-firmenich’s integrated portfolio is designed to excel. The company’s ability to co-create a plant-based food product that is both high in protein and clean-label (a legacy DSM strength) while also possessing an authentic, savory taste and aroma (a legacy Firmenich strength) provides a distinct competitive advantage. This integrated capability allows dsm-firmenich to capture a larger share of its customers’ innovation budgets and solidify its role as a strategic partner rather than a commoditized supplier, which is fundamental to achieving its revenue synergy goals.

B. Competitive Positioning: The “Big Four” and Niche Players

The F&F and specialty ingredients landscape is highly consolidated, dominated by a select group of large, multinational players. The “Big Four” — dsm-firmenich, Givaudan, International Flavors & Fragrances (IFF), and Symrise — collectively command a majority of the global market, with estimates of their combined share ranging from over 53% to as high as 80% in certain sub-segments.³⁴

• Givaudan (GIVN.SW): As a pure-play leader in flavors and fragrances, Givaudan is a primary competitor, particularly for the P&B and TTH divisions. The company reported strong 2024 sales of CHF 7.4 billion (approximately €7.8 billion), with its Fragrance & Beauty division growing an impressive 14.1% on a like-for-like basis.³⁴ Givaudan’s focused business model and consistent performance often earn it a premium valuation multiple from the market.
• International Flavors & Fragrances (IFF.N): IFF is another key competitor with a broad portfolio. The company reported full-year 2024 net sales of $11.48 billion (approximately €10.7 billion).³⁴ IFF has been navigating its own large-scale integration following the transformative acquisition of DuPont’s Nutrition & Biosciences business. This has presented significant challenges, including a high debt load and operational complexities, which have impacted its recent financial performance and stock valuation relative to its peers.
• Symrise (SY1.DE): With 2024 sales of €5.0 billion, Symrise is a direct and formidable competitor with a well-balanced portfolio across its Scent & Care and Taste, Nutrition & Health segments.³⁹ The company has a strong track record of profitable growth and strategic acquisitions.
• Other Competitors: Beyond the Big Four, the competitive landscape includes large agricultural processors with significant nutrition divisions, such as Archer-Daniels-Midland (ADM) and Cargill, which are major players in food ingredients and animal nutrition.⁴¹ Additionally, a vibrant tier of specialized and regional F&F houses, including
  MANE, Takasago, and Robertet, compete effectively in niche markets.³⁴

C. Industry Consolidation and M&A Trends

The broader specialty chemicals sector, including ingredients, has been characterized by a persistent trend of portfolio optimization through mergers, acquisitions, and divestitures.⁴⁵ The dsm-firmenich merger is the most prominent recent example of large-scale, transformational consolidation aimed at creating a more defensible and integrated business model.

The prevailing M&A activity in 2024-2025 has been concentrated in small to mid-sized transactions. Corporations are actively divesting non-core or lower-margin assets to streamline operations and focus on core competencies, while private equity firms remain active buyers, particularly of corporate carve-outs.⁴⁵ dsm-firmenich’s own strategy aligns perfectly with this industry trend. The company is not only integrating a major merger but is also actively “tuning” its portfolio through strategic divestitures, such as the sales of its yeast extract business, marine lipids activities, and its minority stake in Robertet.⁴⁷ This proactive portfolio management is a key element of its strategy to focus on its highest-growth, highest-margin segments.

D. Global Regulatory Frameworks: A Complex Web of Compliance

The food, beverage, and personal care ingredients industries are governed by a complex and increasingly stringent set of regulations that vary significantly across major global markets. Navigating this regulatory web is a critical operational requirement and a significant barrier to entry.

• Europe (EFSA & ECHA): The European Union has one of the most rigorous regulatory systems in the world. The European Food Safety Authority (EFSA) oversees a science-based, pre-approval process for all food improvement agents, including additives, flavorings, and enzymes.⁵¹ Approved substances are placed on a Union list and assigned an “E number,” signifying they have passed stringent safety assessments.⁵³ The EU’s cosmetics regulations are similarly strict, having banned or restricted over 1,300 chemicals in cosmetic products, a stark contrast to the much shorter list in the United States.⁵⁵
• United States (FDA): In the U.S., the Food and Drug Administration (FDA) is the primary regulator. Food ingredients are managed through two main pathways: a formal Food Additive Petition (FAP) process, which requires pre-market approval, and the Generally Recognized as Safe (GRAS) notification program, where a substance can be used if there is a consensus of scientific expert opinion about its safety for its intended use.⁵⁶ Food labeling is governed by the Federal Food, Drug, and Cosmetic Act (FD&C Act) and the Nutrition Labeling and Education Act (NLEA).⁵⁶
• Asia: The regulatory landscape in Asia is highly fragmented. While the ASEAN Cosmetic Directive (ACD) provides a harmonized framework for ten Southeast Asian nations, modeled on EU principles, its implementation varies by country.⁶⁰ Major individual markets such as China (governed by the National Medical Products Administration – NMPA), Japan (Ministry of Health, Labour and Welfare – MHLW), and South Korea (Ministry of Food and Drug Safety – MFDS) each maintain their own distinct and complex regulatory systems for ingredient approval, product registration, and labeling requirements.⁶³

This divergent and demanding global regulatory environment creates a formidable competitive moat. The substantial investment required for toxicological studies, dossier preparation, and ongoing compliance monitoring favors large, well-capitalized players like dsm-firmenich. These companies possess sophisticated, dedicated regulatory affairs departments and the institutional knowledge to navigate these hurdles, which smaller competitors or new market entrants would find difficult to overcome. While presenting an operational challenge, this regulatory complexity ultimately reinforces the market position of the “Big Four” and makes the industry less susceptible to disruption, underscoring the value of dsm-firmenich’s scale and long-standing global presence.

III. Financial Analysis: Deconstructing Post-Merger Performance

The period following the merger has been one of significant financial transition for dsm-firmenich, marked by external headwinds in 2023 followed by a robust recovery in 2024 and into 2025. This section provides a detailed analysis of the company’s pro forma financial trajectory, segment-level profitability, balance sheet health, and cash flow generation.

A. Pro Forma Financial Trajectory (2022-H1 2025)

To provide a clear view of the combined entity’s performance, the company has released pro forma financial information that presents the historical results of DSM and Firmenich as if they had been a single entity. This data reveals a clear narrative of challenge and recovery.

• Pro Forma 2022 (Baseline): In the year prior to the merger’s completion, the combined entity generated pro forma sales of €13,238 million with an Adjusted EBITDA of €2,275 million, resulting in a strong Adjusted EBITDA margin of 17.2%.¹⁹ This serves as the pre-merger baseline for performance comparison.
• Pro Forma 2023 (A Year of Headwinds): The first full year of combined operations was exceptionally challenging. Pro forma sales declined by 7% to €12,310 million, while Adjusted EBITDA fell by a significant 22% to €1,777 million, compressing the margin to 14.4%.¹⁹ This downturn was driven by two primary factors: an unprecedented cyclical low in vitamin prices, which had an estimated negative impact of approximately €500 million on EBITDA, and a deep, industry-wide customer destocking cycle that suppressed volumes across the nutrition and personal care sectors.¹⁹
• FY 2024 (Strong Rebound): The company executed a strong turnaround in 2024. Sales grew 4% to €12,799 million, and Adjusted EBITDA surged by 19% to €2,118 million, with the margin recovering to 16.5%.⁴⁹ This recovery was multifaceted, driven by the normalization of business conditions as the destocking cycle ended, a significant contribution from internal self-help programs (merger synergies and the vitamin transformation program), and a temporary spike in vitamin prices in the fourth quarter due to a competitor’s supply disruption.⁶⁷
• H1 2025 (Continued Momentum): The positive momentum continued into the first half of 2025. Sales grew a further 3% year-over-year to €6,510 million, while Adjusted EBITDA jumped 29% to €1,260 million. This pushed the Adjusted EBITDA margin to an impressive 19.4%, demonstrating the powerful earnings leverage of the business as volumes recover and cost initiatives take full effect.¹¹

The stark contrast between the 2023 results and the subsequent recovery highlights the high degree of operating leverage within the business. The volatility in group-level earnings was almost entirely attributable to the ANH segment’s exposure to the vitamin cycle and the broad, but temporary, impact of customer destocking. The underlying profitability of the core Perfumery & Beauty and Taste, Texture & Health businesses remained robust throughout this period. This dynamic strongly validates the strategic rationale for separating the ANH business; its removal is expected to create a more stable, predictable, and ultimately more highly valued financial profile for the remaining company.

Metric	Pro Forma 2022	Pro Forma 2023	FY 2024	H1 2024	H1 2025
Net Sales (€M)	13,238	12,310	12,799	6,298	6,510
Adjusted EBITDA (€M)	2,275	1,777	2,118	976	1,260
Adj. EBITDA Margin (%)	17.2%	14.4%	16.5%	15.5%	19.4%
Core Adj. Net Profit (€M)	1,013	555	849	365	537
Core Adj. EPS (€)	3.76	2.03	3.10	1.35	1.92
Source: dsm-firmenich Financial Reports 11

B. Segment Performance and Profitability Deep Dive

A granular look at the business units reveals the distinct performance drivers and margin profiles that constitute the group’s results. The core consumer-facing businesses have demonstrated consistent strength and high profitability, while the ANH segment has been the primary source of volatility.

Segment	FY 2023 (Pro Forma)	FY 2024	H1 2025
Perfumery & Beauty (P&B)
Sales (€M)	3,709	3,964 (+7%)	1,989 (-1%)
Adj. EBITDA (€M)	783	882 (+13%)	438 (-4%)
Adj. EBITDA Margin (%)	21.1%	22.3%	22.0%
Taste, Texture & Health (TTH)
Sales (€M)	3,038	3,245 (+7%)	1,686 (+3%)
Adj. EBITDA (€M)	556	615 (+11%)	339 (+10%)
Adj. EBITDA Margin (%)	18.3%	19.0%	20.1%
Health, Nutrition & Care (HNC)
Sales (€M)	2,270	2,214 (-2%)	1,072 (-2%)
Adj. EBITDA (€M)	389	371 (-5%)	192 (+11%)
Adj. EBITDA Margin (%)	17.1%	16.8%	17.9%
Animal Nutrition & Health (ANH)
Sales (€M)	3,227	3,324 (+3%)	1,751 (+14%)
Adj. EBITDA (€M)	128	343 (+168%)	342 (+293%)
Adj. EBITDA Margin (%)	4.0%	10.3%	19.5%
Source: dsm-firmenich Financial Reports 11

Analysis of Segment Performance:

• Perfumery & Beauty (P&B): This segment has been a standout performer, delivering very strong results in 2024 with a 7% sales increase and a 13% rise in Adjusted EBITDA, pushing its margin to an impressive 22.3%. The slight decline in H1 2025 was against a very strong prior-year comparable and was primarily due to softness in high-margin suncare products, while the core Perfumery business remained robust.⁶⁸
• Taste, Texture & Health (TTH): TTH has also delivered a very strong performance, with 7% sales growth in 2024 and continued momentum into 2025. This growth is supported by strong volumes and the successful realization of sales synergies from cross-selling integrated taste and ingredient solutions.⁶⁸
• Health, Nutrition & Care (HNC): This segment experienced a weaker 2023 and a slight sales decline in 2024, reflecting the lingering effects of destocking in dietary supplements. However, business momentum improved significantly in the second half of 2024 and into 2025, with Adjusted EBITDA growing 11% in H1 2025, driving a 200bps margin improvement to 17.9%.⁶⁷
• Animal Nutrition & Health (ANH): The ANH segment’s results clearly illustrate the volatility the company seeks to exit. After a collapse in profitability in 2023 (4.0% margin), the segment saw a massive 168% rebound in Adjusted EBITDA in 2024. This was further amplified in H1 2025, where the margin reached 19.5%, heavily influenced by temporary vitamin price spikes.¹¹

C. Balance Sheet Health and Capital Structure

dsm-firmenich maintains a strong balance sheet and is committed to a solid investment-grade credit profile, which provides crucial financial flexibility to execute its complex strategic transformation.

• Debt Structure: As of December 31, 2024, the company’s total borrowings amounted to €5.28 billion, an increase from €4.83 billion at year-end 2023.⁷⁰ The debt portfolio is composed primarily of long-term debenture loans (€4.45 billion), supplemented by private loans, lease liabilities, and short-term credit facilities. The company maintains a €2 billion commercial paper program for managing short-term liquidity needs.⁷⁰ To optimize its debt maturity profile and secure favorable rates, the company has been active in capital markets, issuing a new €750 million 11-year bond in February 2025 with a 3.38% coupon and redeeming a €750 million hybrid bond in July 2025.⁴⁸
• Net Debt and Leverage: Reported net debt stood at €2.56 billion at the end of 2024.⁴⁹ S&P Global Ratings estimated the company’s adjusted debt-to-EBITDA leverage ratio to be a healthy 1.7x-1.9x for 2024, with funds from operations (FFO) to debt at a strong 45%-50%.⁷² Management has communicated a commitment to maintaining a reported net leverage target of 1.5x to 2.5x.⁷²
• Credit Ratings: The company’s financial strength is affirmed by its solid investment-grade credit ratings from the two major agencies it engages with:

• Moody’s: A3 (long-term) / P-2 (short-term), with a Stable outlook, last updated in April 2025.⁷⁰
• S&P Global Ratings: A- (long-term) / A-2 (short-term), with a Stable outlook, last updated in February 2025.⁷⁰
• The company is not rated by Fitch and has explicitly stated it does not provide information to Scope Ratings.⁷⁰
• Financial Covenants: An important feature of the company’s financing arrangements is the absence of financial covenants in its outstanding bonds, which provides significant operational and strategic flexibility.⁷⁷

This strong investment-grade status is a key competitive advantage. It ensures reliable access to capital markets at attractive costs, enabling the company to comfortably fund its integration and restructuring programs, capital expenditures, and substantial shareholder returns without financial strain. This financial stability provides the firepower for future bolt-on acquisitions and stands in contrast to more highly leveraged peers, who may be constrained in their ability to invest for growth.

D. Cash Flow Generation and Working Capital Efficiency

A key focus for management post-merger has been on improving cash generation, which saw a marked improvement in 2024.

• Free Cash Flow: Adjusted gross operating free cash flow increased by 55% in 2024, reaching €1,552 million, up from €999 million in pro forma 2023.⁶⁷ This strong performance was a result of both the robust EBITDA recovery and a disciplined approach to working capital management, particularly the reduction of inventory levels that had been built up during the supply chain disruptions of the previous year.⁶⁶
• Cash Conversion: The company’s cash-to-sales conversion ratio (Adjusted gross operating free cash flow as a percentage of sales) reached an excellent 12.1% in 2024, exceeding its mid-term strategic target of over 10%.⁴⁹ While cash flow in the first half of 2025 was weaker at €215 million (versus €460 million in H1 2024) due to the timing of certain payments and higher employee rewards, management has reiterated its confidence in meeting the full-year target, citing a typically stronger cash flow performance in the second half of the year.¹¹
• Working Capital Management: Operating working capital stood at €3.8 billion at the end of H1 2025, representing 29.6% of sales.⁶⁹ The company has stated a continued commitment to structurally reduce its working capital levels as a percentage of sales, which will be a key driver of future free cash flow generation.⁶⁹

IV. Strategic Direction and Capital Deployment

dsm-firmenich’s management team has articulated and is actively executing a clear, multi-faceted strategy designed to reshape the company into a more focused, higher-growth, and more profitable enterprise. This strategy is supported by a disciplined capital allocation framework that balances investment in growth with robust returns to shareholders.

A. Portfolio Optimization: The ANH Separation and Strategic Divestitures

The most significant strategic initiative post-merger is the comprehensive reshaping of the company’s portfolio.

• Separation of Animal Nutrition & Health (ANH): In a decisive move announced in early 2024, dsm-firmenich committed to separating its ANH business from the group.⁴⁹ The strategic rationale is compelling: management concluded that the ANH business, with its distinct market dynamics and capital requirements, could better realize its full potential under a different ownership structure.¹¹ For the remaining dsm-firmenich entity, the separation will achieve several key objectives: it will significantly reduce exposure to the volatile earnings of the vitamin market, lower the overall capital intensity of the group, and sharpen its strategic focus on the consumer-facing businesses.¹¹ The separation process is reported to be well-advanced and entering its final stages as of mid-2025.¹¹ A major milestone in this process was the completion of the sale of dsm-firmenich’s stake in its Feed Enzymes Alliance with Novonesis for €1.5 billion in cash on June 2, 2025.⁴⁷
• Strategic Portfolio Tuning: Concurrent with the ANH separation, the company is actively “tuning” its portfolio by divesting assets deemed non-core or not aligned with its long-term margin and growth ambitions. Throughout 2024, this program saw the successful divestiture of the yeast extract business to Lesaffre, the marine lipids (MEG-3® fish oil) business to KD Pharma Group, and the company’s minority stake in fragrance competitor Robertet for nearly €400 million.⁴⁷ These divestitures are consistent with the overarching strategy to concentrate resources and management attention on the high-growth, high-margin segments of Perfumery & Beauty, Taste, Texture & Health, and Health, Nutrition & Care.⁵⁰

B. Capital Allocation Priorities: R&D, CapEx, and M&A

dsm-firmenich’s capital allocation is prioritized to fuel innovation-led organic growth while selectively pursuing strategic acquisitions.

• Investment in R&D and Innovation: Innovation is positioned as the central pillar of the company’s growth strategy. R&D expenditure is substantial, totaling €796 million in 2024, or 6.2% of net sales. This represents an increase from €744 million (6.0% of sales) in pro forma 2023, demonstrating a continued commitment to science and technology.⁸⁰ The company’s R&D efforts are powered by a team of over 2,000 scientists across 20 global locations and are focused on key innovation platforms such as biotechnology (including precision fermentation), microbiome research, receptor biology, and the application of Artificial Intelligence and data science to accelerate product development.⁸⁰ This level of investment is critical to developing the proprietary, high-performance ingredients that provide a competitive edge.
• Capital Expenditures (CapEx): Investments in property, plant, and equipment are directed towards optimizing the global manufacturing footprint, ensuring supply chain resilience, and adding capacity to support growth in strategic areas. Cash-based CapEx amounted to €764 million in 2024, a modest increase from €734 million in 2023.⁴⁹ In the first half of 2025, CapEx was €401 million, indicating a continued pace of investment.¹¹
• M&A Strategy: While the primary focus since the merger has been on integration and organic growth, the company maintains a strategy of pursuing value-accretive, bolt-on acquisitions. These transactions are targeted at strengthening specific capabilities or gaining access to new technologies within the core business segments. The acquisition of postbiotics pioneer Adare Biome for an enterprise value of €275 million in 2023 is a prime example of this disciplined approach, enhancing the company’s position in the high-growth microbiome space.⁸³ Similarly, the move to increase its ownership stake in texture-ingredient specialist Andre Pectin to 90.5% in April 2025 demonstrates a focus on consolidating positions in core technologies.⁴⁸

The company’s capital allocation strategy reveals a clear and disciplined cycle: divest non-core assets to generate cash, use that cash to de-lever the balance sheet and return capital to shareholders, and simultaneously reinvest in the core business through robust R&D and targeted bolt-on M&A. This disciplined “flywheel” approach to value creation, which balances growth investments with shareholder returns, should be viewed positively as it demonstrates a clear and sustainable strategy, contrasting with potentially riskier, debt-fueled “empire-building” M&A strategies.

C. Shareholder Return Policy: Dividends and Share Repurchases

dsm-firmenich is committed to providing attractive returns to its shareholders through a combination of a stable dividend and significant share buybacks.

• Dividend Policy: The company pursues a policy of paying a stable, and preferably rising, dividend. Reflecting this commitment, the Board proposed and shareholders approved a stable dividend of €2.50 per share for the fiscal year 2024, despite the significant ongoing transformation.⁴⁹ This provides a tangible cash return to investors and signals the Board’s confidence in the company’s underlying cash-generating ability. The company has a long history of consistent dividend payments through its legacy DSM entity.⁸⁵
• Share Buyback Programs: Leveraging the substantial cash proceeds from its strategic divestitures, the company has initiated a major capital return program. In April 2025, dsm-firmenich launched a share repurchase program with an aggregate market value of €1 billion, with the explicit purpose of reducing its issued capital.¹¹ The program’s execution was accelerated, with a completion target of January 30, 2026.¹¹ This large-scale buyback is a strong signal from management that it believes the company’s shares are attractively valued and represents an efficient way to return excess capital to shareholders.

V. Growth Opportunities & Strategic Initiatives

dsm-firmenich is strategically positioned to capitalize on several powerful, long-term secular growth trends. Its integrated capabilities and focus on innovation enable it to pursue multiple avenues for value creation, from leveraging macro-trends to executing specific operational and commercial initiatives.

A. Exposure to Favorable Megatrends

The company’s portfolio is directly aligned with three dominant consumer megatrends that are reshaping the food, beverage, and personal care industries:

• Health and Wellness: A profound global shift in consumer consciousness towards proactive health management is driving demand for products with tangible benefits. This includes demand for fortified foods, dietary supplements, clean-label products with fewer artificial ingredients, and solutions for sugar and salt reduction.²¹ dsm-firmenich’s HNC and TTH divisions are at the heart of this trend, providing vitamins, probiotics, nutritional lipids, and taste modulation technologies that enable healthier consumer products without sacrificing taste.
• Sustainability: Consumers, particularly younger demographics, are increasingly making purchasing decisions based on environmental and social impact. This fuels demand for products with natural and renewable ingredients, sustainable sourcing, transparent supply chains, and a lower carbon footprint.²⁷ The company’s leadership in biotechnology, green chemistry, and its extensive portfolio of natural and biodegradable ingredients (e.g., Clearwood®, Firgood®) position it as a key partner for brands looking to enhance their sustainability credentials.³⁴
• Premiumization and Enhanced Experiences: Rising disposable incomes, particularly in emerging markets, are leading consumers to seek out products that offer superior performance, unique sensory experiences, and a sense of affordable luxury.³¹ The P&B division, especially in fine fragrance and active beauty, and the TTH division, through the creation of novel and exotic flavor profiles, are well-positioned to benefit from this trend.

B. Innovation Platforms and New Product Development

Innovation is the lifeblood of dsm-firmenich and its primary engine for organic growth. The company invests heavily in a number of key science platforms to fuel its product pipeline ⁸⁰:

• Biotechnology and Fermentation: Mastery of microbial systems allows for the sustainable production of a wide range of ingredients, from vitamins and HMOs to novel fragrance molecules. This reduces reliance on traditional chemical synthesis or volatile agricultural sources.
• Microbiome Science: The company is a leader in researching the gut and skin microbiome, developing pre-, pro-, and postbiotic solutions like Humiome® that offer clinically proven health benefits for humans and animals.⁶⁹
• Receptor Biology and Sensory Science: Deep research into how the human body perceives taste and smell enables the creation of highly effective taste modulators (for sugar reduction) and long-lasting, high-impact fragrances.
• AI and Data Science: The use of artificial intelligence is being integrated across the R&D process to accelerate the discovery of new molecules, predict formulation performance, and analyze consumer trend data, significantly improving speed-to-market.

Recent innovations stemming from these platforms include ampli-D®, a next-generation form of Vitamin D with faster bioavailability; life’s®OMEGA, a sustainable, algal-based source of omega-3 fatty acids; and ETERWELL HAIR, a beauty ingredient for scalp vitality based on senolytics science.⁶⁹

C. Cross-Selling and Revenue Synergies

A core component of the merger thesis is the potential to generate significant revenue synergies by cross-selling the combined portfolio to a shared customer base. The company is targeting an incremental €500 million in annual revenues from these synergies, which are expected to contribute approximately €175 million to Adjusted EBITDA at full run-rate.¹¹ These synergies are being realized through:

• Integrated Solutions: Offering customers a single-partner solution for complex product development that combines taste, texture, health, and scent. The successful collaboration with dairy customer Alpura in Mexico to solve a regulatory, taste, and nutrition challenge is a prime example of this strategy in action.⁷
• Capability Sharing: Leveraging Firmenich’s deep consumer insights and creation expertise across DSM’s customer base, and introducing DSM’s scientific and health ingredient portfolio to Firmenich’s clients.
• Geographic Reach: Utilizing the combined global sales force to introduce products from one legacy company into markets where the other had a stronger presence.

The company reported that sales synergies contributed approximately €50 million in revenues in 2024 and are showing good momentum, with a steadily growing project pipeline.⁶⁷ The majority of these synergies (60%) are expected to be realized in the TTH division, with 25% in HNC and 15% in P&B.⁴⁹

D. Geographic Expansion in Emerging Markets

As highlighted by its geographic revenue breakdown, dsm-firmenich has a strong platform for growth in emerging markets across Asia and Latin America, which together account for 42% of sales.¹² These regions are projected to be the fastest-growing markets for food, beverage, and personal care products, driven by urbanization, rising incomes, and the expansion of the middle class.¹³ The company’s strategy involves leveraging its global operational footprint and innovation centers, such as its recently transformed facility in Singapore, to develop and deliver locally relevant solutions that cater to the specific tastes and preferences of consumers in these key growth regions.⁹⁰

VI. Recent Challenges & Headwinds (2022-2024)

The period surrounding the merger and the initial phase of integration was marked by a confluence of significant macroeconomic and industry-specific challenges. These headwinds severely impacted the company’s financial performance in 2023, though conditions have markedly improved since.

• Integration Complexity and Execution Risks: Merging two global companies of the scale of DSM and Firmenich is an inherently complex undertaking. The process involves integrating distinct corporate cultures, harmonizing IT systems and business processes, and aligning strategic priorities across a vast and diverse organization. Executing this integration while simultaneously navigating external market turmoil presents a significant management challenge and carries inherent execution risks.
• Inflationary Pressure on Raw Materials: The 2022-2023 period was characterized by significant global inflation, which drove up the cost of key raw materials, energy, and transportation.⁹¹ As an ingredients producer, the company faced margin pressure as it worked to pass these higher input costs through to customers via price increases, often with a time lag.⁷⁵ The company’s TTH division has actively developed solutions to help customers navigate this by reducing reliance on high-cost raw materials like cocoa and vanilla.⁶⁹
• Supply Chain Disruptions: Global supply chains remained volatile post-pandemic, exacerbated by geopolitical events. The vitamin market, in particular, experienced significant disruptions. In 2023, dsm-firmenich undertook a major restructuring of its vitamin activities, including the closure of facilities in China, to address profitability issues.¹⁹ In 2024, the market was further disrupted by a fire at a competitor’s plant in Germany, which led to a force majeure declaration and a sharp, albeit temporary, spike in prices for vitamins A and E.⁹⁴ These events highlight the ongoing supply chain risks in key product areas.
• Customer Destocking Cycle: The most significant headwind in 2023 was a deep and prolonged destocking cycle across the consumer goods industry. Following a period of significant inventory building in 2021 and 2022 to mitigate supply chain risks, customers aggressively reduced their own inventory levels in 2023, leading to a sharp drop in order volumes for ingredient suppliers.⁶⁶ This “persistent destocking” was a primary driver of the weak performance in the HNC and ANH segments in 2023.¹⁹ By 2024, this cycle had largely ended, leading to a rebound in volumes as customer order patterns normalized.⁶⁷
• Currency Headwinds: As a global company with a Swiss Franc and Euro reporting base but significant sales in US dollars and other currencies, dsm-firmenich is exposed to foreign exchange fluctuations. The strength of the Swiss Franc and negative foreign exchange effects had an adverse impact on reported results, particularly in 2023 and 2024. For example, legacy Firmenich reported a CHF 54 million negative impact on Adjusted EBITDA from FX in H1 2023 ⁹⁸, and the combined company estimated a negative FX effect of €50 million on Adjusted EBITDA in 2024.⁶⁷ A €25 million negative FX impact was recorded in the first half of 2025 alone.⁹⁹
• Geopolitical Tensions and China Exposure: Rising geopolitical tensions, particularly between the US and China, create uncertainty for global supply chains.¹⁶ With 9% of its sales in China and a significant manufacturing and sourcing presence in the country, dsm-firmenich is exposed to risks related to trade policies, tariffs, and potential supply disruptions.¹² European firms, in general, have noted their elevated exposure to critical inputs from China.¹⁷
• Economic Slowdown and Discretionary Spending: While a significant portion of dsm-firmenich’s portfolio serves non-cyclical end markets like food and health, its Perfumery & Beauty segment has exposure to more discretionary consumer spending. An economic slowdown could lead consumers to trade down to lower-priced products or reduce purchases of premium items like fine fragrances.¹⁰¹ However, the beauty industry has historically shown resilience, often benefiting from the “lipstick effect,” where consumers continue to purchase small luxury items during economic downturns.¹⁰¹

VII. Valuation Considerations

Assessing the valuation of dsm-firmenich requires a multi-faceted approach that considers its current trading multiples relative to peers, the intrinsic value of its distinct business segments, and the potential for a re-rating as its strategic transformation progresses. This analysis does not provide a price target but outlines a framework for evaluating the company’s market value.

A. Trading Multiples versus Peer Group

A common method for valuation is to compare a company’s trading multiples, such as Enterprise Value to EBITDA (EV/EBITDA) and Price to Earnings (P/E), against those of its closest competitors. The primary peer group for dsm-firmenich’s core consumer-facing businesses consists of Givaudan, IFF, and Symrise.

Company	Market Cap (approx.)	EV/EBITDA (LTM)	P/E (TTM, Non-GAAP)
dsm-firmenich AG	€26.3B / $28.1B	14.1x – 19.5x	~105x (GAAP)
Givaudan SA	CHF 38.7B / ~$42B	20.6x – 23.8x	~35.5x
IFF Inc.	$28.7B	16.3x – 16.5x	~17.6x
Symrise AG	€12.7B / ~$13.8B	13.9x – 15.6x	~26.7x
Note: Multiples are based on data from various sources as of late 2024/early 2025 and can fluctuate. dsm-firmenich’s P/E is distorted by one-off merger-related accounting; forward multiples are more relevant. Sources: 104

Analysis of Multiples:

• Givaudan consistently trades at a significant premium to the group, reflecting its status as a pure-play market leader with a strong track record of consistent growth and high margins. Its EV/EBITDA multiple is typically in the low-to-mid 20s.
• dsm-firmenich and IFF currently trade at a discount to Givaudan. dsm-firmenich’s LTM EV/EBITDA multiple is reported in a range from approximately 14x to 19.5x across different data providers and calculation methods. IFF’s valuation has been compressed due to its high leverage and the challenges of integrating the DuPont N&B business.
• Symrise generally trades at a multiple between that of IFF/dsm-firmenich and the premium valuation of Givaudan.

The valuation discount for dsm-firmenich relative to Givaudan can be attributed to several factors: its historical conglomerate structure, the earnings volatility and lower margins of the ANH business, and the perceived execution risk associated with a large-scale merger. A key part of the investment thesis is that as the company successfully separates ANH and demonstrates consistent performance in its focused portfolio, this valuation gap should narrow.

B. Sum-of-the-Parts (SOTP) Analysis Framework

Given dsm-firmenich’s structure as a multi-divisional company undergoing significant portfolio changes, a Sum-of-the-Parts (SOTP) valuation is a particularly relevant analytical framework.¹¹⁵ This methodology involves valuing each business segment individually as if it were a standalone entity and then aggregating these values to arrive at a total enterprise value for the group.

A hypothetical SOTP analysis would proceed as follows:

1. Value Perfumery & Beauty (P&B): This segment, with its high margins (22.3% in 2024) and strong market position, would likely be valued using multiples of pure-play fragrance and beauty ingredient peers, potentially warranting a premium multiple close to that of Givaudan’s fragrance division.
2. Value Taste, Texture & Health (TTH): This division would be benchmarked against flavor and food ingredient peers. Its strong growth and synergy potential would support a robust valuation, likely in line with peers like Symrise or the higher end of the food ingredients sector.
3. Value Health, Nutrition & Care (HNC): This segment would be valued against a basket of specialty nutrition and pharma ingredient companies. Its exposure to high-growth areas like medical nutrition and dietary supplements would be a key valuation driver.
4. Value Animal Nutrition & Health (ANH): This business would be valued based on multiples for animal health and feed additive companies. Its valuation would likely be tempered by the cyclicality of the vitamin market. The €1.5 billion sale price for the Feed Enzymes Alliance provides a recent, concrete valuation marker for a part of this business.
5. Aggregate and Adjust: The standalone enterprise values of the four segments would be summed. From this total, the company’s net corporate debt and other corporate-level adjustments would be subtracted to arrive at an implied equity value for the entire company.¹¹⁵

An SOTP analysis can highlight potential hidden value within the conglomerate and is a useful tool for assessing whether the market is fully appreciating the quality of the individual business units, particularly the high-margin P&B and TTH segments.

C. Cash Flow and Dividend Yield

Valuation should also be assessed on the basis of cash generation and shareholder returns.

• Free Cash Flow (FCF) Yield: Based on the strong adjusted gross operating free cash flow of €1.55 billion in 2024 and a market capitalization of approximately €28 billion, the company generated a trailing FCF yield of around 5.5%. A sustainable and growing free cash flow stream is a fundamental driver of long-term value. The company’s target of a >10% cash-to-sales conversion ratio underpins the potential for strong future FCF generation.⁴⁹
• Dividend Yield: The proposed dividend of €2.50 per share for 2024 provides a tangible return to shareholders. Based on recent share prices, this translates to a dividend yield of approximately 2.2% to 2.5%.⁸⁵ The stability of this dividend, even through the recent challenging period, provides a degree of valuation support.

VIII. Synergy Realization & Integration Risks

The successful realization of targeted merger synergies is a critical component of the investment case for dsm-firmenich. Management has laid out a clear plan and is reporting consistent progress, though execution risks inherent in such a large-scale integration remain.

A. Progress on Synergy Targets

dsm-firmenich is on track to achieve its total announced synergy target, which is expected to contribute approximately €350 million to Adjusted EBITDA on an annual run-rate basis once fully implemented.¹¹ This target is composed of two distinct streams:

1. Cost Synergies (~€175 million): Approximately half of the total synergy target is expected to come from cost efficiencies. These savings are being realized through the optimization of the combined organizational structure, procurement savings from leveraging greater purchasing scale, and streamlining the supply chain and manufacturing footprint.⁶⁹ The full run-rate for cost synergies is expected to be achieved by the end of the third year post-merger (mid-2026).
2. Revenue Synergies (~€175 million): The other half of the EBITDA benefit is projected to come from incremental revenues of €500 million, driven by the complementary capabilities of the merged entities.¹¹ These synergies are being captured through cross-selling, developing integrated solutions for customers, and leveraging the combined innovation pipeline. The full run-rate for revenue synergies is expected by the end of the fourth year (mid-2027). The majority of these revenue synergies are targeted in the TTH division (60%), followed by HNC (25%) and P&B (15%).⁴⁹

Reported Progress:

• Cumulative Realization: Since the merger began, the company has realized a cumulative contribution of €165 million to Adjusted EBITDA from synergies as of H1 2025.¹¹ This includes over €120 million realized by the end of 2024.⁴⁹
• 2025 Target: For the full year 2025, the company expects to realize a further contribution of approximately €100 million to Adjusted EBITDA from synergies, with €45 million of this having been achieved in the first half of the year.¹¹

It is important to note that the company is also executing a separate vitamin transformation program, which is expected to generate an estimated €200 million in annual Adjusted EBITDA contribution. These savings are incremental to the €350 million merger synergy target.¹¹ This program contributed ~€100 million in 2024 and is expected to deliver the remaining ~€100 million in 2025.⁴⁹

B. Integration Risks and Mitigation

Despite the positive progress reported, the integration of two large, global organizations with distinct histories and cultures is fraught with potential risks.

• Cultural Integration Challenges: Firmenich was a private, family-owned Swiss company for over 125 years, while DSM was a publicly-listed Dutch science-based company with roots in state mining.⁶ Merging these different corporate cultures requires careful management to ensure alignment, collaboration, and a shared sense of purpose. The establishment of a balanced Executive Committee with representation from both legacy companies is a key step in mitigating this risk.²
• Customer Retention and Business Disruption: During the integration process, there is a risk of business disruption that could impact customer service levels. Competitors may try to exploit any uncertainty to win over customers. Management’s stated focus on maintaining superior customer service and ensuring safety of supply, even at the cost of temporarily higher inventories in 2023, indicates an awareness of this risk.⁹³
• Key Talent Retention: The success of the merged entity, particularly its innovation capabilities, depends on retaining key talent, including perfumers, flavorists, and R&D scientists. Uncertainty during a merger can lead to the departure of valuable employees. The company must execute its organizational restructuring in a way that retains and motivates its top talent.
• Complexity of Systems Integration: Integrating complex enterprise resource planning (ERP) systems, supply chain logistics, and R&D platforms across a global network is a major technical and operational challenge. Delays or issues in this area could hamper the realization of cost synergies and operational efficiencies.

IX. Risk Factors

An investment in dsm-firmenich is subject to a range of risks, from macro-level economic and geopolitical factors to company-specific execution challenges. A comprehensive assessment must consider the following key risk factors.

• Integration and Execution Risks: The primary risk facing the company in the near term is the successful execution of its post-merger integration and strategic transformation. Potential delays in realizing cost and revenue synergies, difficulties in harmonizing corporate cultures, or disruptions arising from the complex separation of the ANH business could negatively impact financial performance and investor confidence.
• Raw Material Price Volatility and Margin Pressure: The company’s profitability is sensitive to fluctuations in the price of its raw materials, which include agricultural commodities, petrochemical derivatives, and natural extracts. Significant and rapid increases in input costs, as seen during the inflationary period of 2022-2023, can compress margins if they cannot be fully and promptly passed on to customers through price increases.⁹¹
• Economic Sensitivity of Discretionary End Markets: While much of the company’s portfolio serves resilient consumer staples markets, the Perfumery & Beauty segment, particularly fine fragrances and premium beauty ingredients, is exposed to discretionary consumer spending. A significant global economic slowdown could lead to reduced consumer demand in these higher-margin categories.¹⁰¹
• Competition: The company operates in highly competitive global markets against large, well-capitalized peers like Givaudan, IFF, and Symrise, as well as numerous specialized and regional players.³⁴ Intense competition can lead to pricing pressure and requires continuous investment in innovation to maintain a competitive edge.
• Regulatory Changes: The food, beverage, and cosmetics industries are subject to stringent and evolving safety, labeling, and environmental regulations across the globe (e.g., EFSA in Europe, FDA in the US, NMPA in China). Changes in these regulations could require costly product reformulations, restrict the use of certain ingredients, or delay new product launches, thereby impacting sales and profitability.⁵¹
• Currency Translation and Transaction Risks: As a global company reporting in Euros but with significant operations and sales in other currencies (notably the US Dollar, Swiss Franc, and Chinese Yuan), dsm-firmenich is exposed to foreign exchange risk. Adverse movements in currency exchange rates can negatively impact reported revenues and profits (translation risk) and affect the cost of raw materials or the profitability of cross-border transactions (transaction risk).¹⁹
• Supply Chain and Geopolitical Risks: The company relies on a complex global supply chain for sourcing raw materials and manufacturing products. This chain is vulnerable to disruptions from geopolitical events, trade disputes, natural disasters, or pandemics. The company’s significant presence in China, both as a market and a manufacturing hub, represents a specific point of geopolitical risk.¹²
• Debt Refinancing and Interest Rate Sensitivity: While the company currently maintains a strong balance sheet, it has a substantial amount of debt. An increase in global interest rates would raise the cost of refinancing existing debt or issuing new debt to fund future investments or acquisitions, potentially impacting net income and cash flow.

X. Segment-Specific Analysis

A deeper analysis of dsm-firmenich’s core business units reveals the specific market dynamics and growth drivers that will shape the future of the company post-ANH separation.

A. Perfumery & Beauty (P&B)

This segment is a global powerhouse, combining Firmenich’s creative leadership in fragrance with DSM’s scientific expertise in personal care ingredients.

• Dynamics: The segment serves a broad range of markets, from luxury fine fragrances to ingredients for everyday consumer products like shampoo, soap, and skin cream. The fine fragrance market is driven by premiumization and innovation in niche scents, while the consumer fragrance and personal care ingredients markets are driven by demand for performance, sustainability, and sensory experience.¹⁴
• Key Trends and Opportunities:

• Natural and Sustainable Ingredients: There is immense consumer demand for “clean beauty,” driving the need for biodegradable fragrances, renewable raw materials, and upcycled ingredients. dsm-firmenich is a leader in this area with its biotechnology platforms and innovations like Clearwood® and the Firgood® collection.³⁴
• Active Beauty: The convergence of beauty and healthcare is creating demand for cosmetic ingredients with scientifically proven benefits (e.g., anti-aging, skin barrier repair, scalp health). DSM’s legacy in skin and sun care provides a strong foundation, with innovations like ETERWELL HAIR targeting specific consumer needs.⁶⁹
• Regulatory Compliance: With tightening regulations on cosmetic ingredients, particularly in Europe and Asia, the ability to provide a comprehensive portfolio of safe and compliant ingredients is a key competitive advantage.⁶⁰

B. Taste, Texture & Health (TTH)

The TTH division is the primary vehicle for delivering on the promise of integrated solutions for the food and beverage industry.

• Dynamics: This segment addresses the complex challenge of creating food and beverage products that are simultaneously healthy, delicious, affordable, and sustainable. It competes in the vast global market for food flavors, texturants, and health ingredients.
• Key Trends and Opportunities:

• Health & Wellness: This is the dominant driver, creating demand for taste modulation solutions that enable the reduction of sugar, salt, and fat without compromising taste. The company’s TastePRINT® technology is a key innovation in this space.¹¹⁸
• Protein Transition: As consumers increasingly adopt plant-based diets, there is a critical need for ingredients that can improve the taste and texture of meat and dairy alternatives. TTH’s integrated portfolio of flavors, texturants, and nutritional ingredients is perfectly positioned to serve this high-growth market.¹⁰
• Clean Label and Naturalness: Consumers are demanding shorter, more understandable ingredient lists. This drives demand for natural flavors, colors, and preservatives, an area where both legacy companies have strong capabilities.²⁷
• Cost Optimization for Customers: In an inflationary environment, TTH can act as a key partner for food manufacturers by providing innovative solutions, such as its Maxiren®EVO coagulant for cheese, that improve efficiency and reduce reliance on volatile or high-cost raw materials.⁶⁹

C. Health, Nutrition & Care (HNC)

The HNC segment is the company’s pure-play health science division, targeting markets where nutritional interventions can have a significant impact on human health and well-being.

• Dynamics: This segment operates in markets with high scientific and regulatory barriers to entry, including dietary supplements, early life nutrition, medical nutrition, and pharmaceuticals. Growth is driven by an aging global population, rising healthcare costs, and a growing consumer focus on preventative health.
• Key Trends and Opportunities:

• Personalized Nutrition: Advances in science and technology are enabling the development of nutritional solutions tailored to individual needs. HNC’s broad portfolio of vitamins, lipids, and other bioactives makes it a key enabler of this trend.
• Gut Health and the Microbiome: This is a major innovation platform for the company. HNC is developing a range of pre-, pro-, and postbiotic ingredients (e.g., Humiome®) that are clinically proven to support gut health, which is increasingly linked to overall immunity, mental well-being, and metabolic health.⁶⁹
• Early Life Nutrition: Providing optimal nutrition in the first 1,000 days of life is critical for long-term health. dsm-firmenich is a leader in key ingredients for infant formula, such as HMOs (Human Milk Oligosaccharides) and algal-based omega-3s, which support cognitive and immune development.⁶⁹
• Pharma Solutions: The segment also provides functional pharma ingredients, such as specialty excipients, that improve the performance, stability, and patient compliance of drug formulations.⁹

XI. Conclusion

The merger of DSM and Firmenich has created a formidable new leader in the global ingredients landscape, uniquely positioned at the intersection of nutrition, health, and beauty. The strategic rationale for the combination is sound, creating an integrated innovation partner with a portfolio breadth and depth that is unmatched by its peers. The company’s initial post-merger period was defined by significant external challenges, most notably the 2023 customer destocking cycle and vitamin price trough, which temporarily obscured the underlying strength and profitability of its core businesses.

However, the robust financial recovery in 2024 and into 2025, coupled with the disciplined execution of its strategic priorities, provides compelling evidence that the company is on the right path. The planned separation of the Animal Nutrition & Health business is a pivotal and value-accretive move that will transform dsm-firmenich into a more focused, less volatile, and higher-margin company, more closely aligned with the resilient growth dynamics of consumer-facing end markets. Management’s disciplined capital allocation—channeling proceeds from strategic divestitures into a significant share buyback program while maintaining investment in innovation—further reinforces confidence in its value creation strategy.

The company is on track to deliver its ambitious synergy targets, which, combined with the successful vitamin transformation program, are providing a powerful tailwind to earnings growth. While significant integration and execution risks remain, the progress to date has been encouraging. Looking forward, the key catalysts for investors will be the successful and timely completion of the ANH separation, the continued delivery of both cost and revenue synergies, and sustained innovation-led organic growth in its three core pillars. As dsm-firmenich completes its transformation and its more stable, high-quality earnings profile becomes evident to the market, a potential re-rating of its valuation multiples closer to those of its pure-play peers represents the central long-term investment thesis.

Works cited

1. About dsm-firmenich – Integrated Annual Report 2024, accessed August 5, 2025, https://annualreport.dsm-firmenich.com/2023/our-company/about-dsm-firmenich.html
2. A merger of equals – Investors – DSM-Firmenich, accessed August 5, 2025, https://investors.dsm-firmenich.com/en/investors/historical-information/dsm-firmenich.html
3. Firmenich International SA financial statements for 2024 – DSM, accessed August 5, 2025, https://our-company.dsm-firmenich.com/en/our-company/news/press-releases/legacy-archive/firmenich/firmenich-international-sa-financial-statements-for-2024.html
4. Firmenich €41 billion merger of equals with DSM – Davis Polk, accessed August 5, 2025, https://www.davispolk.com/experience/firmenich-eu41-billion-merger-equals-dsm
5. DSM-Firmenich, accessed August 5, 2025, https://www.dsm-firmenich.com/en/home.html
6. dsm-firmenich’s journey – Investors, accessed August 5, 2025, https://investors.dsm-firmenich.com/en/investors/historical-information/dsm-firmenichs-journey.html
7. dsm-firmenich Integrated Annual Report 2023, accessed August 5, 2025, https://annualreport.dsm-firmenich.com/2023/
8. Financial results – Investors – DSM-Firmenich, accessed August 5, 2025, https://investors.dsm-firmenich.com/en/investors/results/financial-results.html
9. Financial calendar – Investors – DSM-Firmenich, accessed August 5, 2025, https://investors.dsm-firmenich.com/en/investors/financial-calendar.html
10. Contact Investor Relations – Investors – DSM-Firmenich, accessed August 5, 2025, https://investors.dsm-firmenich.com/en/investors/investor-contacts.html
11. dsm-firmenich reports H1 2025 results, accessed August 5, 2025, https://our-company.dsm-firmenich.com/en/our-company/news/press-releases/2025/dsm-firmenich-reports-h1-2025-results.html
12. Segment information – dsm-firmenich Integrated Annual Report 2024, accessed August 5, 2025, https://annualreport.dsm-firmenich.com/2024/financial-statements/consolidated-financial-statements/notes/segment-information.html
13. Personal Care Specialty Ingredients Market Size Report, 2030 – Grand View Research, accessed August 5, 2025, https://www.grandviewresearch.com/industry-analysis/personal-care-specialty-ingredients-market
14. Beauty and Personal Care Products Market Size & Trends Report, 2030, accessed August 5, 2025, https://www.mordorintelligence.com/industry-reports/global-beauty-and-personal-care-products-market-industry
15. Food Flavors Market Size, Share, Growth | Global Report [2032] – Fortune Business Insights, accessed August 5, 2025, https://www.fortunebusinessinsights.com/food-flavors-market-102745
16. China’s strategy on critical minerals surpasses geopolitics – The World Economic Forum, accessed August 5, 2025, https://www.weforum.org/stories/2024/11/china-critical-mineral-strategy-beyond-geopolitics/
17. European firms facing geopolitical risk: Evidence from recent Eurosystem surveys – CEPR, accessed August 5, 2025, https://cepr.org/voxeu/columns/european-firms-facing-geopolitical-risk-evidence-recent-eurosystem-surveys
18. China’s deteriorating FDI environment for foreign firms | Article – Hinrich Foundation, accessed August 5, 2025, https://www.hinrichfoundation.com/research/article/us-china/rising-challenges-for-foreign-firms-in-china/
19. Financial Performance – dsm-firmenich Integrated Annual Report 2023, accessed August 5, 2025, https://annualreport.dsm-firmenich.com/2023/business/financial-performance.html
20. DSM-Firmenich AG (DSFIY) Q2 2025 Earnings Call Transcript | Seeking Alpha, accessed August 5, 2025, https://seekingalpha.com/article/4807350-dsm-firmenich-ag-dsfiy-q2-2025-earnings-call-transcript
21. Top 10 Trends in Food Ingredients and Dietary Supplements for 2025, accessed August 5, 2025, https://www.ulprospector.com/knowledge/18670/fb-top-10-trends-in-food-ingredients-and-dietary-supplements-for-2025-insights-for-formulators-manufacturers-and-marketers/
22. Global ingredients trends 2025. Quality and health go together, accessed August 5, 2025, https://www.innovamarketinsights.com/trends/global-ingredients-trends-2025/
23. Revealed: the top nutrition trends shaping 2025 – FrieslandCampina Ingredients, accessed August 5, 2025, https://www.frieslandcampinaingredients.com/insight/wellness-rebooted-experts-discuss-the-5-nutrition-trends-set-to-shape-2025/
24. 2025 Consumer Food Trends: Prioritizing Health and Nutrition – Food Industry Executive, accessed August 5, 2025, https://foodindustryexecutive.com/2025/02/2025-consumer-food-trends-prioritizing-health-and-nutrition/
25. Nutritional Ingredients Market Size, Share, Industry, Forecast and outlook (2024-2031), accessed August 5, 2025, https://www.datamintelligence.com/research-report/nutritional-ingredients-market
26. 2025 Ingredient Trends Update | Flavor Trends | AIFI – American International Foods, accessed August 5, 2025, https://www.americaninternationalfoods.com/2025/06/03/2025-ingredient-trends-update/
27. Flavors and Fragrances Strategic Market Opportunities: Trends 2025 …, accessed August 5, 2025, https://www.datainsightsmarket.com/reports/flavors-and-fragrances-1074569
28. Flavors And Fragrances Market Report 2025-2034 – The Business Research Company, accessed August 5, 2025, https://www.thebusinessresearchcompany.com/report/flavors-and-fragrances-global-market-report
29. Flavors And Fragrances Market Size & Share Report, 2030 – Grand View Research, accessed August 5, 2025, https://www.grandviewresearch.com/industry-analysis/flavors-fragrances-market
30. Flavors And Fragrances Market Size & Forecast, 2025-2032 – Coherent Market Insights, accessed August 5, 2025, https://www.coherentmarketinsights.com/market-insight/flavors-and-fragrances-market-5582
31. Personal Care Ingredients Market Size | Global Industry Forecast, accessed August 5, 2025, https://www.marketsandmarkets.com/Market-Reports/personal-care-ingredients-market-251972200.html
32. Personal Care Ingredients Market Size | Industry Forecast, 2031, accessed August 5, 2025, https://www.alliedmarketresearch.com/personal-care-ingredients-market
33. Personal Care Ingredients Market Size to Hit USD 25.96 Billion by 2034, accessed August 5, 2025, https://www.precedenceresearch.com/personal-care-ingredients-market
34. Perfume Ingredient Chemicals Market – Top Companies …, accessed August 5, 2025, https://www.credenceresearch.com/news/perfume-ingredient-chemicals-market-top-companies-comprehensive-analysis
35. Flavor and Fragrance Sales Market, Report Size, Worth, Revenue …, accessed August 5, 2025, https://reports.valuates.com/market-reports/QYRE-Auto-22F6638/global-flavor-and-fragrance
36. Flavors & Fragrances Companies, Top Flavors & Fragrances …, accessed August 5, 2025, https://www.marketsandmarkets.com/ResearchInsight/flavors-fragrance-market.asp
37. Flavor and Fragrance Sector Continues to Blossom – Lincoln International LLC, accessed August 5, 2025, https://www.lincolninternational.com/perspectives/articles/flavor-and-fragrance-sector-continues-to-blossom/
38. Investors | Givaudan, accessed August 5, 2025, https://www.givaudan.com/investors
39. Group management report – Symrise, accessed August 5, 2025, https://symrise.com/corporatereport/2024/home/Symrise_GB24_Lagebericht_EN_geschuetzt.pdf
40. The most important information for investors – Symrise, accessed August 5, 2025, https://www.symrise.com/investors/
41. Top Taste Modulators Companies: DSM (Netherlands), International Flavors & Fragrances Inc. (US), Givaudan (Switzerland), Kerry Group PLC (Ireland), and Ingredion (US) – MarketsandMarkets, accessed August 5, 2025, https://www.marketsandmarkets.com/ResearchInsight/taste-modulator-market.asp
42. Animal Feed Micronutrients Market Size, Share & 2030 Growth Trends Report, accessed August 5, 2025, https://www.mordorintelligence.com/industry-reports/animal-feed-micronutrients-market
43. Animal Nutrition Chemicals Market Size Worth USD 77.32 – GlobeNewswire, accessed August 5, 2025, https://www.globenewswire.com/news-release/2025/06/02/3091773/0/en/Animal-Nutrition-Chemicals-Market-Size-Worth-USD-77-32-Billion-by-2031-Rising-Requirement-for-High-Quality-and-Nutritious-Animal-Feed-Fuels-the-Demand-The-Insight-Partners.html
44. Flavors and Fragrances key companies focusing on technological advancement to gain competitive edge, accessed August 5, 2025, https://www.maximizemarketresearch.com/competitive-analysis/flavors-and-fragrances-manufacturers/269539/
45. Chemicals: US Deals 2025 midyear outlook: PwC, accessed August 5, 2025, https://www.pwc.com/us/en/industries/industrial-products/library/chemicals-deals-outlook.html
46. Chemicals M&A Investment Banking Review of 2024 & Outlook for …, accessed August 5, 2025, https://www.natriumcapital.com/blog/chemicals-ma-investment-banking-review-2024-outlook-for-2025/
47. News – DSM-Firmenich, accessed August 5, 2025, https://our-company.dsm-firmenich.com/en/our-company/news.html
48. Investors – DSM-Firmenich, accessed August 5, 2025, https://investors.dsm-firmenich.com/en/investors.html
49. dsm-firmenich reports full year 2024 results Management Report, accessed August 5, 2025, https://www.dsm-firmenich.com/content/dam/dsm-firmenich/investors/documents/results-center/2025/press-release-dsm-firmenich-fy-2024-report-20250213.pdf
50. dsm-firmenich reports full year 2024 results, accessed August 5, 2025, https://our-company.dsm-firmenich.com/en/our-company/news/press-releases/2025/dsm-firmenich-reports-full-year-2024-results.html
51. EFSA Ingredient Compliance for Europe | GRAS Experts, accessed August 5, 2025, https://grasexperts.com/efsa-ingredient-compliance-for-europe/
52. Food ingredients | EFSA, accessed August 5, 2025, https://www.efsa.europa.eu/en/topics/topic/food-ingredients
53. Food additives – EFSA – European Union, accessed August 5, 2025, https://www.efsa.europa.eu/en/topics/topic/food-additives
54. EU Rules – food additives – Food Safety – European Union, accessed August 5, 2025, https://food.ec.europa.eu/food-safety/food-improvement-agents/additives/eu-rules_en
55. How to find EU approved (or safe) self care and cosmetics in the US – Reddit, accessed August 5, 2025, https://www.reddit.com/r/TheGirlSurvivalGuide/comments/mgo6ne/how_to_find_eu_approved_or_safe_self_care_and/
56. Guidance for Industry: Food Labeling Guide – FDA, accessed August 5, 2025, https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-food-labeling-guide
57. Understanding How the FDA Regulates Food Additives and GRAS Ingredients, accessed August 5, 2025, https://www.fda.gov/food/food-additives-and-gras-ingredients-information-consumers/understanding-how-fda-regulates-food-additives-and-gras-ingredients
58. Substances Added to Food (formerly EAFUS) – FDA, accessed August 5, 2025, https://www.fda.gov/food/food-additives-petitions/food-additive-status-list
59. 21 CFR Part 101 — Food Labeling – eCFR, accessed August 5, 2025, https://www.ecfr.gov/current/title-21/chapter-I/subchapter-B/part-101
60. ASEAN Cosmetic Directive – Health Sciences Authority (HSA), accessed August 5, 2025, https://www.hsa.gov.sg/cosmetic-products/asean-cosmetic-directive
61. Regulatory overview of cosmetic products – Health Sciences Authority (HSA), accessed August 5, 2025, https://www.hsa.gov.sg/cosmetic-products/overview
62. Cosmetics Regulations in ASEAN countries: the ASEAN Cosmetic Directive – Registrar Corp, accessed August 5, 2025, https://www.registrarcorp.com/blog/cosmetics/cosmetic-regulations/cosmetics-regulations-asean/
63. A Guide to Cosmetics Regulations in Asia – Plevenn, accessed August 5, 2025, https://www.plevenn.com/blogs/a-guide-to-cosmetics-regulations-in-asia
64. APAC Cosmetic Regulations: Key Developments in 2024, accessed August 5, 2025, https://connect.in-cosmetics.com/regulations/apac-cosmetic-regulations-2024/
65. dsm-firmenich provides additional pro forma financial information for …, accessed August 5, 2025, https://www.dsm-firmenich.com/content/dam/dsm-firmenich/investors/documents/results-center/2023/press-release-dsm-firmenich-updated-2022-pro-forma-financials-20231004.pdf
66. dsm-firmenich reports 2023 full year results, accessed August 5, 2025, https://our-company.dsm-firmenich.com/en/our-company/news/press-releases/2024/dsm-firmenich-reports-2023-full-year-results.html
67. Financial results – Integrated Annual Report 2024 – DSM-Firmenich, accessed August 5, 2025, https://annualreport.dsm-firmenich.com/2024/our-businesses/financial-performance/financial-results.html
68. dsm-firmenich Q1 2025 trading update Management Report, accessed August 5, 2025, https://www.dsm-firmenich.com/content/dam/dsm-firmenich/investors/documents/results-center/2025/press-release-dsm-firmenich-q1-2025.pdf
69. Presentation to Investors – DSM-Firmenich, accessed August 5, 2025, https://our-company.dsm-firmenich.com/content/dam/dsm-firmenich/investors/documents/results-center/2025/presentation-to-investors-dsm-firmenich-h1-2025.pdf
70. Debt & Credit – Investors – DSM-Firmenich, accessed August 5, 2025, https://investors.dsm-firmenich.com/en/investors/debt-credit.html
71. dsm-firmenich issues €750 million long-term bond, accessed August 5, 2025, https://our-company.dsm-firmenich.com/en/our-company/news/press-releases/2025/dsm-firmenich-issues-750-million-long-term-bond.html
72. Bulletin: DSM-Firmenich’s 2024 Results Show It’s | S&P Global Ratings, accessed August 5, 2025, https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/3323969
73. Firmenich International SA Credit Rating – S&P Global, accessed August 5, 2025, https://disclosure.spglobal.com/ratings/en/regulatory/org-details/sectorCode/CORP/entityId/674436
74. S&P Global Ratings affirms DSM-Firmenich at “A-” (Local Currency LT credit rating); outlook stable – Cbonds, accessed August 5, 2025, https://cbonds.com/news/2789277/
75. Subsidiaries DSM Affirmed At ‘A-‘, Firmenich Upgraded To ‘A-‘; Outlook Stable – S&P Global Ratings, accessed August 5, 2025, https://disclosure.spglobal.com/en/regulatory/article/-/view/sourceId/12705333
76. S&P Global Ratings affirms DSM-Firmenich at “A-” (Local Currency LT credit rating); outlook stable – Cbonds, accessed August 5, 2025, https://cbonds.com/news/3319109/
77. DSM achieve: Debt & credit – Investors, accessed August 5, 2025, https://investors.dsm-firmenich.com/en/investors/historical-information/dsm-archive/debt-credit.html
78. ESG ratings and certifications – dsm-firmenich Integrated Annual Report 2024, accessed August 5, 2025, https://annualreport.dsm-firmenich.com/2024/sustainability/stakeholder-engagement/esg-ratings-and-certifications.html
79. dsm-firmenich reports H1 2025 results – GlobeNewswire, accessed August 5, 2025, https://www.globenewswire.com/news-release/2025/07/31/3124639/0/en/dsm-firmenich-reports-H1-2025-results.html
80. Our approach to Science & Research – Integrated Annual Report 2024, accessed August 5, 2025, https://annualreport.dsm-firmenich.com/2024/our-company/science-research/our-approach-to-science-research.html
81. Science & Research – dsm-firmenich Integrated Annual Report 2023, accessed August 5, 2025, https://annualreport.dsm-firmenich.com/2023/our-company/science-research.html
82. Innovation Services | dsm-firmenich Health, Nutrition & Care, accessed August 5, 2025, https://www.dsm-firmenich.com/en/businesses/health-nutrition-care/expert-services/innovation-services.html
83. News archive | DSM & Firmenich, accessed August 5, 2025, https://our-company.dsm-firmenich.com/en/our-company/news/press-releases/legacy-archive.html
84. dsm-firmenich shareholders approve all resolutions at Annual General Meeting 2024, accessed August 5, 2025, https://our-company.dsm-firmenich.com/en/our-company/news/press-releases/2024/dsm-firmenich-shareholders-approve-all-resolutions-at-annual-general-meeting-2024.html
85. DSM-Firmenich AG dividends – Digrin, accessed August 5, 2025, https://www.digrin.com/stocks/detail/DSM.AS/
86. dsm-firmenich announces increase in share repurchase program to reduce capital to €1 billion, accessed August 5, 2025, https://our-company.dsm-firmenich.com/en/our-company/news/press-releases/2025/dsm-firmenich-announces-increase-in-share-repurchase-program-to-reduce-capital-to-1-billion.html
87. dsm-firmenich | Globenewswire – Via Ritzau, accessed August 5, 2025, https://via.ritzau.dk/pressemeddelelse/14511170/dsm-firmenich?publisherId=90446&lang=en
88. Perfume Market Size, Share, Growth, Industry Analysis, 2032 – Fortune Business Insights, accessed August 5, 2025, https://www.fortunebusinessinsights.com/perfume-market-102273
89. Our markets – dsm-firmenich Integrated Annual Report 2024, accessed August 5, 2025, https://annualreport.dsm-firmenich.com/2024/our-businesses/taste-texture-health/our-markets.html
90. Press Releases – Cargill, accessed August 5, 2025, https://www.cargill.com/news/press-releases
91. FIRMENICH DELIVERS RECORD RESULTS DESPITE CHALLENGING MACRO-ECONOMIC ENVIRONMENT – PR Newswire, accessed August 5, 2025, https://www.prnewswire.com/in/news-releases/firmenich-delivers-record-results-despite-challenging-macro-economic-environment-877845707.html
92. FIRMENICH DELIVERS RECORD RESULTS DESPITE CHALLENGING MACRO-ECONOMIC ENVIRONMENT, accessed August 5, 2025, https://www.dsm-firmenich.com/content/dam/dsm-firmenich/investors/documents/historical-information/firmenich/publications/pr-firmenich-fy22-results.pdf
93. Firmenich delivers strong results in half of fiscal year 2023 – DSM, accessed August 5, 2025, https://our-company.dsm-firmenich.com/en/our-company/news/press-releases/legacy-archive/firmenich/firmenich-delivers-strong-results-first-half-fiscal-year-2023.html
94. The Global Vitamin Market: Navigating Volatility in Q4 2024 – DSM-Firmenich, accessed August 5, 2025, https://www.dsm-firmenich.com/anh/en_NA/news/articles/the-global-vitamin-market-navigating-volatility-in-q4-2024.html
95. dsm-firmenich Q3 2024 trading update Management Report, accessed August 5, 2025, https://www.dsm-firmenich.com/content/dam/dsm-firmenich/investors/documents/results-center/2024/dsm-firmenich-press-release-q3-2024-trading-update.pdf
96. CHEMICAL INSIGHTS – Grace Matthews, accessed August 5, 2025, https://gracematthews.com/wp-content/uploads/2024/02/2024-Winter-Chemical-Newsletter.pdf
97. Nouryon reports full-year 2024 results with adjusted EBITDA growing 9.5 percent and margins expanding 220 basis points over prior year, accessed August 5, 2025, https://www.nouryon.com/news-and-events/news-overview/2025/nouryon-reports-full-year-2024-results/
98. FIRMENICH DELIVERS STRONG RESULTS IN FIRST HALF OF FISCAL YEAR 2023, accessed August 5, 2025, https://www.dsm-firmenich.com/content/dam/dsm-firmenich/investors/documents/historical-information/firmenich/publications/pr-firmenich-hy23-results-press-release.pdf
99. DSM Firmenich AG (DSMFF) (H1 2025) Earnings Call Highlights: Strong Organic Growth and – Investing.com Canada, accessed August 5, 2025, https://ca.investing.com/news/company-news/dsm-firmenich-ag-dsmff-h1-2025-earnings-call-highlights-strong-organic-growth-and–4131220
100. The New Global Supply Chain: The Domino Effect of Geopolitical Tensions between China and the United States – Inbound Logistics, accessed August 5, 2025, https://www.inboundlogistics.com/articles/the-new-global-supply-chain-the-domino-effect-of-geopolitical-tensions-between-china-and-the-united-states/
101. State of Beauty 2025: Solving a shifting growth puzzle – McKinsey, accessed August 5, 2025, https://www.mckinsey.com/industries/consumer-packaged-goods/our-insights/state-of-beauty
102. The beauty boom and beyond: Can the industry maintain its growth? – McKinsey, accessed August 5, 2025, https://www.mckinsey.com/industries/consumer-packaged-goods/our-insights/the-beauty-boom-and-beyond-can-the-industry-maintain-its-growth
103. Beauty Inflation Surge: Tackling Margin Pressures and Uncertainty | Market Research Report | Euromonitor, accessed August 5, 2025, https://www.euromonitor.com/beauty-inflation-surge-tackling-margin-pressures-and-uncertainty/report
104. DSM Firmenich AG (DSFI) EV/EBITDA – Investing.com UK, accessed August 5, 2025, https://uk.investing.com/pro/XWBO:DSFI/explorer/ev_to_ebitda_ltm
105. DSM-Firmenich AG (DSMFF) – Statistics – Twelve Data, accessed August 5, 2025, https://twelvedata.com/markets/108332/stock/otc/dsmff/statistics
106. DSFIR Relative Valuation – DSM-Firmenich AG – Alpha Spread, accessed August 5, 2025, https://www.alphaspread.com/security/aex/dsfir/relative-valuation/enterprise-value-to-ebitda
107. Givaudan (GVDNY) Statistics & Valuation Metrics – Stock Analysis, accessed August 5, 2025, https://stockanalysis.com/quote/otc/GVDNY/statistics/
108. Givaudan (SWX:GIVN) Statistics & Valuation Metrics – Stock Analysis, accessed August 5, 2025, https://stockanalysis.com/quote/swx/GIVN/statistics/
109. EV / EBITDA For Givaudan SA (0QPS) – Finbox, accessed August 5, 2025, https://finbox.com/LSE:0QPS/explorer/ev_to_ebitda_ltm/
110. EV / EBITDA For International Flavors & Fragrances Inc (IFF) – Finbox, accessed August 5, 2025, https://finbox.com/NYSE:IFF/explorer/ev_to_ebitda_ltm/
111. International Flavors & Fragrances Inc. (IFF) Stock Valuation Grade & Metrics, accessed August 5, 2025, https://seekingalpha.com/symbol/IFF/valuation/metrics
112. Symrise AG (SYIEF) Statistics & Valuation Metrics – Stock Analysis, accessed August 5, 2025, https://stockanalysis.com/quote/otc/SYIEF/statistics/
113. EV / EBITDA For Symrise AG (SY1) – Finbox, accessed August 5, 2025, https://finbox.com/DB:SY1/explorer/ev_to_ebitda_ltm/
114. Symrise AG (SY1) – Statistics – Twelve Data, accessed August 5, 2025, https://twelvedata.com/markets/670993/stock/xetr/sy1/statistics
115. Sum-of-the-Parts Valuation (SOTP) Meaning, Formula, Example – Investopedia, accessed August 5, 2025, https://www.investopedia.com/terms/s/sumofpartsvaluation.asp
116. firmenich-sustainability-report-2020.pdf, accessed August 5, 2025, https://www.dsm-firmenich.com/content/dam/dsm-firmenich/investors/documents/historical-information/firmenich/firmenich-sustainability-report-2020.pdf
117. Material risks and uncertainties – Integrated Annual Report 2024 – DSM-Firmenich, accessed August 5, 2025, https://annualreport.dsm-firmenich.com/2024/governance-risk-management/material-risks-and-uncertainties.html
118. DSM-Firmenich – Annual Report 2024, accessed August 5, 2025, https://www.dsm-firmenich.com/content/dam/dsm-firmenich/investors/documents/historical-information/annual-reports/dsm-bv-annual-report-2024.pdf